Newcastle University

Publications

Year: 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 1987 1986 1984 1983 1980 1979

• Peng, B., Boddy, A. V., Cole, M., Pearson, A. D. J., Chatelut, E., Rubie, H., Newell, D. R.
  Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients
  . European Journal of Cancer 1995, 31(11), 1804-1810.
• Carr M, May FEB, Lennard TWJ, Westley BR. Determination of estrogen responsiveness of breast cancer by competitive reverse transcription polymerase chain reaction. British Journal of Cancer 1995, 72(6), 1427-1434.
• Westley BR, May FEB. In-vitro development of tamoxifen resistance. In: International Meeting on Current Topics in Breast Cancer Research. 1995, Cambridge: Endocrine - Related Cancer.
• Westley BR, May FEB. Insulin like growth factors: the unrecognised oncogenes. British Journal of Cancer 1995, 72(5), 1065-1066.
• Hodgson DR, May FEB, Westley BR. Mutations at position-11 and postition-60 of insulin like growth factor 1 reveal differences between its interactions with the type-I insulin like growth factor receptor and insulin receptor. European Journal of Biochemistry 1995, 233(1), 299-309.
• Chadwick MP, May FEB, Westley BR. Production and comparison of mature single domain trefoil peptides PNR-2/PS2 CYS(58) and PNR-2/PS2 SER(58). Biochemical Journal 1995, 308, 1001-1007.
• Calvert AH, Boddy AV, Bailey NP, Siddiqui N, Humphreys A, Hughs A, Robson L, Gumbrell L, Thomas H, Chapman F, Proctor M, Simmons D, Oakey A, Lind MJ, Sinha DV, Newell DR. Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. Seminars in Oncology 1995, 22(5 Suppl. 12), 91-98.
• Rafi, I., Taylor, G. A., Calvete, J. A., Boddy, A. V., Balmanno, K., Bailey, N., Lind, M., Calvert, A. H., Webber, S., Jackson, R. C., Johnston, A., Clendeninn, N., Newell, D. R. Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridplthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion. Clinical Cancer Research 1995, 1(11), 1275-1284.
• Wedge SR, Laohavinij S, Taylor GA, Boddy AV, Calvert AH, Newell DR. Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) administered with an oral folic acid supplement. Clinical Cancer Research 1995, 1(12), 1479-1486.
• Hawkins JM, Bain BJ, Mehta AB, Moorman AV. Complex hyperdiploidy in acute myeloid leukaemia: a United Kingdom Cancer Cytogenetics Group Study. Leukemia Research 1995, 19(12), 905-913.
• Bourne Y, Arvai AS, Bernstein SL, Watson MH, Reed SI, Endicott JE, Noble ME, Johnson LN, Tainer JA. Crystal structure of the cell cycle-regulatory protein suc1 reveals a beta-hinge conformational switch. Proceedings of the National Academy of Sciences 1995, 92(22), 10232-10236.
• Yule, S. M., Boddy, A. V., Cole, M., Price, L., Wyllie, R., Tasso, M. J., Pearson, A. D. J., Idle, J. R. Cyclophosphamide Metabolism in Children. Cancer Research 1995, 55(4), 803-809.
• May FEB, Westley BR. Estrogen regulated messenger RNAs in human breast cancer cells. Biomedicine & Pharmacotherapy 1995, 49(9), 400-414.
• Austin CA, Marsh KL, Wasserman RA, Willmore E, Sayer PJ, Wang JC, Fisher LM. Expression, domain structure and enzymatic properties of an active recombinant human DNA topoisomerase II beta. Journal of Biological Chemistry 1995, 270(26), 15739-15746.
• Owen DJ, Papageorgiou AC, Garman EF, Noble MEM, Johnson LN. Expression, purification and crystallisation of phosphorylase kinase catalytic domain. Journal of Molecular Biology 1995, 246(3), 374-381.
• Griffin, R. J., Pemberton, L. C., Rhodes, D., Bleasdale, C., Bowman, K., Calvert, A. H., Curtin, N. J., Durkacz, B. W., Newell, D. R., Porteous, J. K., Golding, B. T. Novel potent inhibitors of the DNA-repair enzyme poly (ADP-ribose)polymerase (PARP). Anti-Cancer Drug Design 1995, 10(6), 507-514.
• Boulton, S., Pemberton, L. C., Porteous, J. K., Curtin, N. J., Griffin, R. J., Golding, B. T., Durkacz, B. W. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. British Journal of Cancer 1995, 72(4), 849-856.
• Craft, A. W., Parker, L., Stiller, C., Cole, M. Screening for wilms' tumor in patients with aniridia, Beckwith syndrome, or hemihypertrophy. Medical and Pediatric Oncology 1995, 24(4), 231-234.
• Endicott JA, Nurse P. The cell cycle and suc1: From structure to function?. Structure 1995, 3(4), 321-325.
• Brown NR, Noble MEM, Endicott JA, Garman EF, Wakatsuki S, Mitchell E, Rasmussen B, Hunt T, Johnson LN. The crystal structure of Cyclin A. Structure 1995, 3(11), 1235-1247.
• Endicott JA, Noble ME, Garman EF, Brown N, Rasmussen B, Nurse P, Johnson LN. The crystal structure of p13suc1, a p34cdc2-interacting cell cycle control protein. EMBO Journal 1995, 14(5), 1004-1014.
• Boddy, A. V., Cole, M., Pearson, A. D. J., Idle, J. R. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemotherapy and Pharmacology 1995, 36(1), 53-60.
• Griffin RJ, Curtin NJ, Newell DR, Golding BT, Durkacz BW, Calvert AH. The Role of Inhibitors of Poly(Adp-Ribose) Polymerase as Resistance-Modifying Agents in Cancer-Therapy. Biochimie 1995, 77(6), 408-422.
• Owen DJ, Noble MEM, Garman EF, Papageorgiou AC, Johnson LN. Two structures of the catalytic domain of phosphorylase kinase: an active protein kinase complexed with substrate analogue and product. Structure 1995, 3(5), 467-482.
• Cole M, Craft AW, Parker L, Bell S, Seviour JA, McGill AC, Dale G. Urinary creatinine adjusted reference ranges for homovanillic and vanillylmandelic acid in children and adults. Clinica Chimica Acta 1995, 236(1), 19-32.